Portola partners with J&J, Bayer on bloodthinner antidote

Portola Pharmaceuticals has signed on to see if its antidote to Factor Xa inhibitors--PRT4445--will help make the blood-thinner Xarelto safer. Xarelto's owners, Bayer and J&J, will pay Portola an unspecified sum in the deal, which follows a similar pact struck with Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) for their blood-thinner. In both cases Portola held on to worldwide rights for the drug. Story

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.